TheTechno Optimist.

Latent-X2 & Latent-YLatent Labs—Latent Labs launches Latent-Y, an agent that runs antibody design campaignsLatent-X2 & Latent-YLatent Labs—Latent Labs unveils Latent-X2, generating drug-like antibodies without optimisation rounds

Latent Labs

Generative protein and antibody design models

GB/USprivateest. 2023latentlabs.com (opens latentlabs.com)Checked 11 Oct

The brief

Analyst view
  • AlphaFold predicts the shape of existing proteins; Latent Labs designs new ones that bind a chosen target.
  • Latent-Y (March 2026) is an agent that runs an antibody design campaign from a written goal to lab-ready designs.
  • Launched with $50M (Radical Ventures, Sofinnova); models run in London, wet lab in San Francisco.

Technical approach

As reported
All-atom

Design every atom

Its models generate a protein's sequence and full 3D structure together, down to individual atoms, for a target never seen before.

Zero-shot

Fewer rounds of optimisation

The aim is drug-like antibodies on the first try, skipping months of lab tweaking that usually follow a first hit.

Platform

Models, not a drug pipeline

It sells access and partnerships to drug makers instead of developing its own medicines.

Primer